HEMATOLOGY

Shared insight on methods to identify blastic plasmacytoid dendritic cell neoplasm followed by updated classifications from the World Health Organization.

Broad perspective on diagnosis of the myeloproliferative neoplasms via optimal workup and molecular testing.

A comprehensive overview of myeloproliferative neoplasms followed by insight on the differences between essential thrombocytopenia, polycythemia vera, and myelofibrosis.

In an interview with Targeted Oncology, Nicholas J. Short, MD, discussed the evolution of the treatment landscape for acute lymphoblastic leukemia and what he hopes is next to come.

In an interview with Targeted Oncology, Tapan M. Kadia, MD, discussed the changes seen in the treatment landscape for patients with acute myeloid leukemia, specifically highlighting elderly and/or unfit patients.

At the 2022 NCCN: Hematologic Malignancies Conference, a panel discussion gave an overview of current treatment trends for acute myeloid leukemia, as well as supportive care measures to utilize during therapy.

Additional data emerged demonstrating the value of blinatumomab not only in patients with relapsed acute lymphoblastic leukemia but also in those with detectable minimal residual disease.

Phase 1 results examining azacitidine and venetoclax in high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia elicited an overall response rate of 87%.

In comparison with conventional transplant options, Orca-T may be more effective with a lower probability of infection in patients with hematologic malignancies.

Jorge J. Castillo, MD, will explore the challenges of managing WM. He will present on September 30, 2022, at 11:04 AM.

Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.

Lionel Adès, MD, PhD, discussed emerging targeted therapies for myelodysplastic syndromes during a presentation at the 10th Annual Meeting of the Society of Hematologic Oncology.

Combinations of the BCL2 inhibitor venetoclax with hypomethylating agents are undergoing investigation to determine benefit in high-risk myelodysplastic syndrome.

In the myeloma space, minimal residual disease negativity is prognostic of progression-free survival in relapsed or refractory patients. In leukemia, the biomarker combined with other prognostication techniques provides complex information that is clinically relevant.

An overview of the single-cell level in early stage disease and describe new molecular classifications of myelodysplastic syndrome.

Opening the discussion on the management of BPDCN, an expert panel consisting of two hematologist-oncologists and a pathologist, considers the causes, incidence and diagnostic approach to this rare disease.

The FDA has approved eflapegrastim-xnst injection for adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs linked with clinically significant incidence of febrile neutropenia.

Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.

Pegfilgrastim-fpgk has been approved by the FDA for patients with febrile neutropenia following data which revealed it to have a high degree of similarity with its reference product.

Data from the phase 2 CADENZA trial revealed front-line pivekimab sunirine to demonstrate clinical activity in patients with blastic plasmacytoid dendritic cell neoplasm.

Nicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.

Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.

An investigational new drug application has been accepted by the FDA allowing for the start of a phase 1 trial to evaluate the tolerability of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies

Approval has been granted by the FDA to pemigatinib for the treatment of patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement based on the phase 2 FIGHT-203 trial.